E-viri
PDF
Recenzirano
Odprti dostop
-
Forde, Patrick M; Chaft, Jamie E; Smith, Kellie N; Anagnostou, Valsamo; Cottrell, Tricia R; Hellmann, Matthew D; Zahurak, Marianna; Yang, Stephen C; Jones, David R; Broderick, Stephen; Battafarano, Richard J; Velez, Moises J; Rekhtman, Natasha; Olah, Zachary; Naidoo, Jarushka; Marrone, Kristen A; Verde, Franco; Guo, Haidan; Zhang, Jiajia; Caushi, Justina X; Chan, Hok Yee; Sidhom, John-William; Scharpf, Robert B; White, James; Gabrielson, Edward; Wang, Hao; Rosner, Gary L; Rusch, Valerie; Wolchok, Jedd D; Merghoub, Taha; Taube, Janis M; Velculescu, Victor E; Topalian, Suzanne L; Brahmer, Julie R; Pardoll, Drew M
New England journal of medicine/The New England journal of medicine, 05/2018, Letnik: 378, Številka: 21Journal Article
In a pilot study, two doses of neoadjuvant nivolumab administered to patients with resectable lung cancer resulted in a major pathological response in 45% and amplified T-cell clones specific for tumor antigens.
